Wei Deng

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano et al. · Journal of Clinical Oncology · 2017 · 345 citations · Full text

Hematological Malignancy, Immunohematology, Momelotinib 200 +13

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Alessandro D. Santin, Wei Deng, Michael Frumovitz et al. · Gynecologic Oncology · 2020 · 149 citations · Full text

Cervical Cancer Management, Phase Ii Evaluation, Cervical Cancer +10

The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy

Wei Deng, Xu Cai, Amy Liu et al. · Radiotherapy and Oncology · 2019 · 82 citations

Surgical Oncology, Esophageal Cancer Patients, Esophagus +9

Long‐term safety and efficacy of deferasirox (Exjade^®) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease

Elliott Vichinsky, Françoise Bernaudin, Gian Luca Forni et al. · British Journal of Haematology · 2011 · 78 citations · Full text

A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix

Charles A. Kunos, Wei Deng, Dawn Dawson et al. · International Journal of Gynecological Cancer · 2015 · 63 citations · Full text